Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Gross Margin for 4 consecutive years, with 43.49% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 1425.0% to 43.49% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 31.4% through Dec 2025, down 468.0% year-over-year, with the annual reading at 31.4% for FY2025, 468.0% down from the prior year.
  • Gross Margin for Q4 2025 was 43.49% at bioAffinity Technologies, up from 34.84% in the prior quarter.
  • The five-year high for Gross Margin was 93.75% in Q2 2023, with the low at 19.92% in Q2 2025.
  • Average Gross Margin over 4 years is 54.74%, with a median of 41.29% recorded in 2024.
  • The sharpest move saw Gross Margin plummeted -6776bps in 2023, then surged 1425bps in 2025.
  • Over 4 years, Gross Margin stood at 92.54% in 2022, then crashed by -73bps to 24.78% in 2023, then increased by 18bps to 29.24% in 2024, then skyrocketed by 49bps to 43.49% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 43.49%, 34.84%, and 19.92% for Q4 2025, Q3 2025, and Q2 2025 respectively.